Article

Practicability of Pharmacogenetics in Transplantation Medicine

1] Departments of Hospital Pharmacy [2] Internal Medicine.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.39). 08/2013; 95(3). DOI: 10.1038/clpt.2013.169
Source: PubMed

ABSTRACT Implementation of pharmacogenetics in transplantation medicine is below the expectations expressed fifteen years ago. Numerous papers reported associations between gene polymorphisms and pharmacokinetics of immunosuppressive drugs. Evidence that genotype-based dosing improves outcome is lacking. Extensive therapeutic drug monitoring (TDM) can rapidly correct for the variability in drug exposure caused by genetic differences. The contribution of genotype-based dosing will be more pronounced for drugs for which pharmacokinetic or pharmacodynamic monitoring is not applied.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 29 August 2013 doi:10.1038/clpt.2013.169.

Full-text

Available from: Dennis A Hesselink, Mar 22, 2014
1 Follower
 · 
68 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetic information is increasingly used to optimize clinical treatment of patients, but obstacles remain to practical implementation as well as challenges to our understanding of genetic variation in drug response. These areas that particularly require research attention include gene-environment interactions, the consequences of genetic variation, and the impact of epigenetics on gene expression and function. In this issue of Clinical Pharmacology & Therapeutics focused on pharmacogenetics, we discuss some of the recent advances in understanding from a variety of viewpoints.
    Clinical Pharmacology &#38 Therapeutics 03/2014; 95(3):231-5. DOI:10.1038/clpt.2013.235 · 7.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This overview describes the full spectrum of current pre-clinical and clinical kidney-, liver-, heart- and lung transplantation research performed in Erasmus MC – University Medical Centre in Rotterdam, The Netherlands. An update is provided on the development of a large living donor kidney transplantation program and on optimization of kidney allocation, including the implementation of a domino kidney-donation program. Our current research efforts to optimize immunosuppressive regiments and find novel targets for immunosuppressive therapy, our recent studies on prevention of ischemia-reperfusion-induced graft injury, our newest findings on stimulation of tissue regeneration, our novel approaches to prevent rejection and viral infection, and our latest insights in the regulation of allograft rejection, are summarized.
    Transplant Immunology 09/2014; DOI:10.1016/j.trim.2014.09.005 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation and its consequent fibrosis are two main features of diabetic nephropathy (DN), but target therapy on these processes for DN remains yet ineffective. We report here that miR-29b is a novel therapeutic agent capable of inhibiting progressive renal inflammation and fibrosis in type 2 diabetes in db/db mice. Under diabetic conditions, miR-29b was largely downregulated in response to advanced glycation end (AGE) product, which was associated with upregulation of collagen matrix in mesangial cells via the transforming growth factor-β (TGF-β)/Smad3-dependent mechanism. These pathological changes were reversed by overexpressing miR-29b, but enhanced by knocking-down miR-29b. Similarly, loss of renal miR-29b was associated with progressive diabetic kidney injury, including microalbuminuria, renal fibrosis, and inflammation. Restored renal miR-29b by the ultrasound-based gene therapy was capable of attenuating diabetic kidney disease. Further studies revealed that inhibition of Sp1 expression, TGF-β/Smad3-dependent renal fibrosis, NF-κB-driven renal inflammation, and T-bet/Th1-mediated immune response may be mechanisms associated with miR-29b treatment in db/db mice. In conclusion, miR-29b may play a protective role in diabetic kidney disease and may have therapeutic potential for diabetic kidney complication.Molecular Therapy (2014); doi:10.1038/mt.2013.235.
    Molecular Therapy 12/2013; 22(4). DOI:10.1038/mt.2013.235 · 6.43 Impact Factor